Prostate cancer is the most diagnosed cancer in men in the U.S. and a leading cause of cancer-related deaths. Key risk factors include age, family history, and lifestyle choices such as diet and smoking. Prostate carcinoma can be localized or metastatic; patients with metastatic castration-sensitive prostate cancer (mCSPC) typically respond to androgen deprivation therapy (ADT), but most eventually develop resistance, progressing to castration-resistant prostate cancer (mCRPC), which carries a poorer prognosis. Bone metastases are prevalent, affecting prognosis and quality of life (QoL) due to complications like pain and skeletal-related events (SREs). Treatment includes systemic therapy to reduce the burden of disease, localized treatment (medication, radiation, or surgery) to prevent SREs, and supportive care to improve mobility, strength, and emotional well-being. Prognosis varies, with isolated bone metastases generally offering better outcomes than those with visceral involvement. Effective management of bone metastases and SREs is critical for enhancing patient QoL and survival in advanced prostate cancer.